Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review

Randall K. Leong; Stefan G. G. de Wachter; Philip E. V. A. Van Kerrebroeck

doi:10.1159/000288223

Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review

Randall K. Leong^*, Stefan G. G. de Wachter, Philip E. V. A. Van Kerrebroeck

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The overactive bladder syndrome (OAB) negatively affects the daily life of many people. Conservative treatments, such as antimuscarinics, do not always lead to sufficient improvement of the complaints and/or are often associated with considerable side effects resulting in treatment failure. In the case of failure or intolerable side effects, sacral neuromodulation (SNM) and botulinum toxin are minimally invasive and reversible alternatives. Currently, of these alternatives only SNM with InterStimTM therapy has FDA approval for use in OAB patients. This review attempts to provide an update on the current position of SNM and botulinum toxin in the second-line management of adults with idiopathic OAB, based on the available clinical evidence concerning the efficacy and safety.

Original language	English
Pages (from-to)	245-253
Journal	Urologia Internationalis
Volume	84
Issue number	3
DOIs	https://doi.org/10.1159/000288223
Publication status	Published - 2010

Keywords

Sacral neuromodulation
Botulinum toxin
Overactive bladder syndrome

Access to Document

10.1159/000288223

Cite this

@article{1c6cc6ba4358477b880f8f4d38157e97,

title = "Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review",

abstract = "The overactive bladder syndrome (OAB) negatively affects the daily life of many people. Conservative treatments, such as antimuscarinics, do not always lead to sufficient improvement of the complaints and/or are often associated with considerable side effects resulting in treatment failure. In the case of failure or intolerable side effects, sacral neuromodulation (SNM) and botulinum toxin are minimally invasive and reversible alternatives. Currently, of these alternatives only SNM with InterStimTM therapy has FDA approval for use in OAB patients. This review attempts to provide an update on the current position of SNM and botulinum toxin in the second-line management of adults with idiopathic OAB, based on the available clinical evidence concerning the efficacy and safety. ",

keywords = "Sacral neuromodulation, Botulinum toxin, Overactive bladder syndrome",

author = "Leong, {Randall K.} and {de Wachter}, {Stefan G. G.} and {Van Kerrebroeck}, {Philip E. V. A.}",

year = "2010",

doi = "10.1159/000288223",

language = "English",

volume = "84",

pages = "245--253",

journal = "Urologia Internationalis",

issn = "0042-1138",

publisher = "Karger",

number = "3",

}

TY - JOUR

T1 - Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review

AU - Leong, Randall K.

AU - de Wachter, Stefan G. G.

AU - Van Kerrebroeck, Philip E. V. A.

PY - 2010

Y1 - 2010

N2 - The overactive bladder syndrome (OAB) negatively affects the daily life of many people. Conservative treatments, such as antimuscarinics, do not always lead to sufficient improvement of the complaints and/or are often associated with considerable side effects resulting in treatment failure. In the case of failure or intolerable side effects, sacral neuromodulation (SNM) and botulinum toxin are minimally invasive and reversible alternatives. Currently, of these alternatives only SNM with InterStimTM therapy has FDA approval for use in OAB patients. This review attempts to provide an update on the current position of SNM and botulinum toxin in the second-line management of adults with idiopathic OAB, based on the available clinical evidence concerning the efficacy and safety.

AB - The overactive bladder syndrome (OAB) negatively affects the daily life of many people. Conservative treatments, such as antimuscarinics, do not always lead to sufficient improvement of the complaints and/or are often associated with considerable side effects resulting in treatment failure. In the case of failure or intolerable side effects, sacral neuromodulation (SNM) and botulinum toxin are minimally invasive and reversible alternatives. Currently, of these alternatives only SNM with InterStimTM therapy has FDA approval for use in OAB patients. This review attempts to provide an update on the current position of SNM and botulinum toxin in the second-line management of adults with idiopathic OAB, based on the available clinical evidence concerning the efficacy and safety.

KW - Sacral neuromodulation

KW - Botulinum toxin

KW - Overactive bladder syndrome

U2 - 10.1159/000288223

DO - 10.1159/000288223

M3 - Article

C2 - 20389150

SN - 0042-1138

VL - 84

SP - 245

EP - 253

JO - Urologia Internationalis

JF - Urologia Internationalis

IS - 3

ER -